Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin.
anterior subcapsular cataract
enfortumab vedotin
urothelial carcinoma
Journal
International medical case reports journal
ISSN: 1179-142X
Titre abrégé: Int Med Case Rep J
Pays: New Zealand
ID NLM: 101566269
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
07
2021
accepted:
07
09
2021
entrez:
11
10
2021
pubmed:
12
10
2021
medline:
12
10
2021
Statut:
epublish
Résumé
Enfortumab vedotin is an antibody-drug conjugate that was recently granted accelerated US Food and Drug Administration approval for the treatment of locally advanced or metastatic urothelial cancer. Early clinical trials identified blurry vision, increased lacrimation and other events associated with dry eye as potential side effects. We report a case of bilateral anterior subcapsular cataract development following initiation of enfortumab vedotin. Enfortumab vedotin is not previously known to cause cataract development or progression and, thus, our patient's presentation may reflect the first report of an undocumented adverse effect of this novel agent.
Identifiants
pubmed: 34629907
doi: 10.2147/IMCRJ.S324394
pii: 324394
pmc: PMC8493475
doi:
Types de publication
Case Reports
Langues
eng
Pagination
707-709Informations de copyright
© 2021 Thibodeau and Nallasamy.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Cells Tissues Organs. 2005;179(1-2):43-55
pubmed: 15942192
Clin Cancer Res. 2021 Feb 15;27(4):922-927
pubmed: 32962979
JAAD Case Rep. 2020 Oct 23;7:57-59
pubmed: 33319007
J Dermatol. 2020 Dec;47(12):1436-1438
pubmed: 32860247
Indian J Ophthalmol. 2014 Feb;62(2):103-10
pubmed: 24618482
JAAD Case Rep. 2021 Jun 04;14:7-9
pubmed: 34235241
Front Oncol. 2021 Mar 04;11:621591
pubmed: 33747934
Hum Genet. 2012 Feb;131(2):235-50
pubmed: 21769484
J Clin Oncol. 2019 Oct 10;37(29):2592-2600
pubmed: 31356140
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234
pubmed: 29032195